A.R.T. Advisors’s Akari Therapeutics AKTX Stock Holding History

A.R.T. Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-27	Closed	-$36K	–	1304
2019 Q3	$36K	Buy	+27	New	+$41.3K	﹤0.01%	1340

Other funds holding AKTX

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

A.R.T. Advisors's AKTX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Akari Therapeutics (AKTX) in Q4 2019, closing a stake of 27 shares — an estimated $36K sold.

A.R.T. Advisors first reported a position in AKTX in Q3 2019 and held it in 1 quarter. The position peaked at $36K in Q3 2019. 13 funds tracked by Wall St. Rank hold AKTX as of Q4 2019.

A.R.T. Advisors reported no remaining Akari Therapeutics position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 27 Akari Therapeutics shares in Q4 2019, an estimated $36K.
A.R.T. Advisors first reported a position in Akari Therapeutics in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Akari Therapeutics position peaked at $36K in Q3 2019.
13 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.